Literature DB >> 25813469

Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review.

Johan A F Koekkoek1, Melissa Kerkhof1, Linda Dirven1, Jan J Heimans1, Jaap C Reijneveld1, Martin J B Taphoorn1.   

Abstract

There is growing evidence that antitumor treatment contributes to better seizure control in low-grade glioma patients. We performed a systematic review of the current literature on seizure outcome after radiotherapy and chemotherapy and evaluated the association between seizure outcome and radiological response. Twenty-four studies were available, of which 10 described seizure outcome after radiotherapy and 14 after chemotherapy. All studies demonstrated improvements in seizure outcome after antitumor treatment. Eight studies reporting on imaging response in relation to seizure outcome showed a seizure reduction in a substantial part of patients with stable disease on MRI. Seizure reduction may therefore be the only noticeable effect of antitumor treatment. Our findings demonstrate the clinical relevance of monitoring seizure outcome after radiotherapy and chemotherapy, as well as the potential role of seizure reduction as a complementary marker of tumor response in low-grade glioma patients.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chemotherapy; epilepsy; glioma; radiotherapy; review

Mesh:

Year:  2015        PMID: 25813469      PMCID: PMC5654353          DOI: 10.1093/neuonc/nov032

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  68 in total

1.  Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study.

Authors:  Gan You; Zhi-Yi Sha; Wei Yan; Wei Zhang; Yong-Zhi Wang; Shao-Wu Li; Lin Sang; Zi Wang; Gui-Lin Li; Shou-Wei Li; Yi-Jun Song; Chun-Sheng Kang; Tao Jiang
Journal:  Neuro Oncol       Date:  2011-12-19       Impact factor: 12.300

Review 2.  Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.

Authors:  Melanie S M van Breemen; Erik B Wilms; Charles J Vecht
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

3.  The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Christian E Elger; Otmar D Wiestler; Johannes Schramm
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

4.  Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors.

Authors:  Christian Plathow; Daniela Schulz-Ertner; Christoph Thilman; Ivan Zuna; Mathias Lichy; Marc-André Weber; Heinz-Peter Schlemmer; Michael Wannenmacher; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-15       Impact factor: 7.038

5.  Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors.

Authors:  Raja B Khan; Arzu Onar
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

6.  Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study.

Authors:  Roberta Rudà; Umberto Magliola; Luca Bertero; Elisa Trevisan; Chiara Bosa; Cristina Mantovani; Umberto Ricardi; Anna Castiglione; Chiara Monagheddu; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2013-07-28       Impact factor: 12.300

7.  Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.

Authors:  A Tosoni; E Franceschi; M Ermani; R Bertorelle; L Bonaldi; V Blatt; Alba A Brandes
Journal:  J Neurooncol       Date:  2008-04-23       Impact factor: 4.130

8.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

9.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

10.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas.

Authors:  Edward F Chang; Matthew B Potts; G Evren Keles; Kathleen R Lamborn; Susan M Chang; Nicholas M Barbaro; Mitchel S Berger
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

View more
  23 in total

1.  How bad are your seizures and did the treatment help?

Authors:  Robin Grant
Journal:  Neuro Oncol       Date:  2016-11-16       Impact factor: 12.300

Review 2.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

Review 3.  Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.

Authors:  Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 4.  Epilepsy in brain metastasis: an emerging entity.

Authors:  Roberta Rudà; Francesca Mo; Alessia Pellerino
Journal:  Curr Treat Options Neurol       Date:  2020-02-08       Impact factor: 3.598

Review 5.  Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.

Authors:  Jan Buckner; Caterina Giannini; Jeanette Eckel-Passow; Daniel Lachance; Ian Parney; Nadia Laack; Robert Jenkins
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

Review 6.  Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma.

Authors:  Brian Stocksdale; Seema Nagpal; John D Hixson; Derek R Johnson; Prashant Rai; Akhil Shivaprasad; Ivo W Tremont-Lukats
Journal:  Neurooncol Pract       Date:  2020-05-20

Review 7.  Seizures and gliomas--towards a single therapeutic approach.

Authors:  Gilles Huberfeld; Charles J Vecht
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

Review 8.  Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Authors:  Edward K Avila; Marc Chamberlain; David Schiff; Jaap C Reijneveld; Terri S Armstrong; Roberta Ruda; Patrick Y Wen; Michael Weller; Johan A F Koekkoek; Sandeep Mittal; Yoshiki Arakawa; Ali Choucair; Jorge Gonzalez-Martinez; David R MacDonald; Ryo Nishikawa; Aashit Shah; Charles J Vecht; Paula Warren; Martin J van den Bent; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-09-20       Impact factor: 12.300

9.  Choice of antiepileptic drugs affects the outcome in cancer patients with seizures.

Authors:  B Cacho-Diaz; D San-Juan; K Salmeron; C Boyzo; N Lorenzana-Mendoza
Journal:  Clin Transl Oncol       Date:  2018-06-04       Impact factor: 3.405

10.  Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study.

Authors:  Aya Haggiagi; Edward K Avila
Journal:  Neurooncol Pract       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.